CA
CHI Advisors Portfolio holdings
AUM
$252M
This Quarter Return
+63.01%
1 Year Return
+57.46%
3 Year Return
+78.52%
5 Year Return
–
10 Year Return
–
AUM
$372M
AUM Growth
+$372M
(+42%)
Cap. Flow
+$17.3M
Cap. Flow
% of AUM
4.64%
Top 10 Holdings %
Top 10 Hldgs %
85.87%
Holding
28
New
2
Increased
12
Reduced
7
Closed
2
Top Buys
| 1 |
Pliant Therapeutics
PLRX
|
$6.33M |
| 2 |
Larimar Therapeutics
LRMR
|
$6.08M |
| 3 |
Repare Therapeutics
RPTX
|
$5.13M |
| 4 |
Keros Therapeutics
KROS
|
$3.64M |
| 5 |
AKUS
Akouos, Inc. Common Stock
AKUS
|
$3.06M |
Top Sells
| 1 |
GTHX
G1 Therapeutics, Inc. Common Stock
GTHX
|
$5.54M |
| 2 |
TSVT
2seventy bio
TSVT
|
$4.21M |
| 3 |
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
|
$4.14M |
| 4 |
Nkarta
NKTX
|
$3.16M |
| 5 |
Entrada Therapeutics
TRDA
|
$1.99M |
Sector Composition
| 1 | Healthcare | 99.68% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Entrada Therapeutics
TRDA
$208M
| – | – |
-163,496
| Closed | -$1.99M |
|
27
SPDR S&P Biotech ETF
XBI
$5.07B
| – | – |
0
| – | – |
|
|
PHAS
28
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
| – | – |
-750,000
| Closed | -$450K |
|